A study evaluating the effectiveness of back up by immunohistochemical staining in non-squamous non-small cell lung carcinoma cases where the driver gene is negative by standard examinations in Toyama.

A study evaluating the effectiveness of back up by immunohistochemical staining in non-squamous non-small cell lung carcinoma cases where the driver gene is negative by standard examinations in Toyama. - A study evaluating the effectiveness of back up by immunohistochemical staining in non-squamous non-small cell lung carcinoma cases where the driver gene is negative by standard examinations in Toyama.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043723

Enrollment

Registered

2021-03-24

Start date

2021-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous non-small cell lung carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following (1) to (5) are targeted. (1) Patients histopathologically diagnosed as non-squamous epithelial non-small cell lung cancer (2) Patients who are undergoing or will be undergoing drug therapy due to the inability to perform curative radical radiation therapy or surgical treatment (3) Patients for whom no significant genetic changes have been detected by standard genetic tests performed in daily practice, or patients for whom standard tests cannot be performed (4) Patients who have residual paraffin-embedded blocks collected in the past and can be immunohistochemically stained (5) Patients who explained to the person using the explanation consent document and obtained written consent

Exclusion criteria

Exclusion criteria: No exclusion criteria will be set for cases that meet the selection criteria and are deemed appropriate by the attending physician.

Design outcomes

Primary

Measure	Time frame
The percentage of positive cases of immunohistochemical staining and comparison with the results of tests that detect other genetic changes	—

Secondary

Measure	Time frame
Percentage of cases treated with molecular-targeted therapies, presence or absence of response	—

Countries

Japan

Contacts

Public ContactTakeshi Tsuda

Toyama Prefectural Central Hospital The Department of Respiratory Medicine

ttsuda-tym@umin.ac.jp076-424-1531

Outcome results